Digitalizing Crime Prevention Theories: How Technology Affects Victim and Offender Behavior

In the last thirty years, two main theoretical traditions in crime prevention literature have emerged: 1) the victimization perspective, which considers the victim, offender, and environment, and 2) the social control perspective, an alternative view that considers the role that community and family members play in informally influencing the moral values of potential offenders. Both of these theories have been used to inform crime prevention techniques by focusing on modifying the behavior of potential victims and the motivations of potential offenders. While both the social control and victimization perspectives have been used to discuss criminal behavior and crime prevention, neither acknowledge the role that technology plays in the lives of those that may commit crimes or be victimized. In this paper, we attempt to “digitalize” theories of crime prevention. By digitalize, we mean to understand how technology use influences the lives of both potential offenders and victims. We explore the theoretical foundations of both the victimization and social control perspectives and discuss their limitations as a result of not considering how technology influences information-seeking practices and communication routines. We argue that examining technology use is essential to crime theories that are used to help understand and predict criminal behavior, and we propose modifications to each framework to increase their effectiveness in predicting criminal behavior and practical application

Financial Analysis for Measuring and Comparing Risk in Grantmaking Portfolios

· Risk has not been treated in a systematic way that allows for a rich understanding of the extent to which foundations are, or should be, incorporating or evaluating risk in philanthropy. · In this article, we conceptualize and develop a tool to evaluate the levels of philanthropic risk that foundations maintain through their grant portfolios. · We create an index of aggregated risk at the portfolio level using several financial indicators based on previous theory and literature. Then, we test the index on a sample of foundations and their grantees in the state of Georgia and compare risk levels across community, corporate, family, independent, and operating foundations. · Our results show small differences in philanthropic risk levels when measured by financially oriented proxies between foundation types

Measures of outer setting constructs for implementation research: a systematic review and analysis of psychometric quality

Background: Despite their influence, outer setting barriers (e.g., policies, financing) are an infrequent focus of implementation research. The objective of this systematic review was to identify and assess the psychometric properties of measures of outer setting used in behavioral and mental health research. Methods: Data collection involved (a) search string generation, (b) title and abstract screening, (c) full-text review, (d) construct mapping, and (e) measure forward searches. Outer setting constructs were defined using the Consolidated Framework for Implementation Research (CFIR). The search strategy included four relevant constructs separately: (a) cosmopolitanism, (b) external policy and incentives, (c) patient needs and resources, and (d) peer pressure. Information was coded using nine psychometric criteria: (a) internal consistency, (b) convergent validity, (c) discriminant validity, (d) known-groups validity, (e) predictive validity, (f) concurrent validity, (g) structural validity, (h) responsiveness, and (i) norms. Frequencies were calculated to summarize the availability of psychometric information. Information quality was rated using a 5-point scale and a final median score was calculated for each measure. Results: Systematic searches yielded 20 measures: four measures of the general outer setting domain, seven of cosmopolitanism, four of external policy and incentives, four of patient needs and resources, and one measure of peer pressure. Most were subscales within full scales assessing implementation context. Typically, scales or subscales did not have any psychometric information available. Where information was available, the quality was most often rated as â 1-minimalâ or â 2-adequate.â Conclusion: To our knowledge, this is the first systematic review to focus exclusively on measures of outer setting factors used in behavioral and mental health research and comprehensively assess a range of psychometric criteria. The results highlight the limited quantity and quality of measures at this level. Researchers should not assume â one size fits allâ when measuring outer setting constructs. Some outer setting constructs may be more appropriately and efficiently assessed using objective indices or administrative data reflective of the system rather than the individual

Enhancing the impact of implementation strategies in healthcare: a research agenda

The field of implementation science was developed to better understand the factors that facilitate or impede implementation and generate evidence for implementation strategies. In this article, we briefly review progress in implementation science, and suggest five priorities for enhancing the impact of implementation strategies. Specifically, we suggest the need to: 1) enhance methods for designing and tailoring implementation strategies; 2) specify and test mechanisms of change; 3) conduct more effectiveness research on discrete, multi-faceted, and tailored implementation strategies; 4) increase economic evaluations of implementation strategies; and 5) improve the tracking and reporting of implementation strategies. We believe that pursuing these priorities will advance implementation science by helping us to understand when, where, why, and how implementation strategies improve implementation effectiveness and subsequent health outcomes

A comparative phase I study of combination, homologous subtype-C DNA, MVA, and Env gp140 protein/adjuvant HIV vaccines in two immunization regimes

There remains an urgent need for a prophylactic HIV vaccine. We compared combined MVA and adjuvanted gp140 to sequential MVA/gp140 after DNA priming. We expected Env-specific CD4+ T-cells after DNA and MVA priming, and Env-binding antibodies in 100% individuals after boosting with gp140 and that combined vaccines would not compromise safety and might augment immunogenicity. Forty volunteers were primed three times with DNA plasmids encoding (CN54) env and (ZM96) gag-pol-nef at 0, 4 and 8 weeks then boosted with MVA-C (CN54 env and gag-pol-nef) and glucopyranosyl lipid adjuvant-aqueous formulation (GLA-AF) adjuvanted CN54gp140. They were randomised to receive them in combination at the same visit at 16 and 20 weeks (accelerated) or sequentially with MVA-C at 16, 20, and GLA-AF/gp140 at 24 and 28 weeks (standard). All vaccinations were intramuscular. Primary outcomes included ≥grade 3 safety events and the titer of CN54gp140-specific binding IgG. Other outcomes included neutralization, binding antibody specificity and T-cell responses. Two participants experienced asymptomatic ≥grade 3 transaminitis leading to discontinuation of vaccinations, and three had grade 3 solicited local or systemic reactions. A total of 100% made anti-CN54gp140 IgG and combining vaccines did not significantly alter the response; geometric mean titer 6424 (accelerated) and 6578 (standard); neutralization of MW965.2 Tier 1 pseudovirus was superior in the standard group (82 versus 45% responders,  = 0.04). T-cell ELISpot responses were CD4+ and Env-dominant; 85 and 82% responding in the accelerated and standard groups, respectively. Vaccine-induced IgG responses targeted multiple regions within gp120 with the V3 region most immunodominant and no differences between groups detected. Combining MVA and gp140 vaccines did not result in increased adverse events and did not significantly impact upon the titer of Env-specific binding antibodies, which were seen in 100% individuals. The approach did however affect other immune responses; neutralizing antibody responses, seen only to Tier 1 pseudoviruses, were poorer when the vaccines were combined and while T-cell responses were seen in >80% individuals in both groups and similarly CD4 and Env dominant, their breadth/polyfunctionality tended to be lower when the vaccines were combined, suggesting attenuation of immunogenicity and cautioning against this accelerated regimen

PAX-D:study protocol for a randomised placebo-controlled trial evaluating the efficacy and mechanism of pramipexole as add-on treatment for people with treatment resistant depression

Introduction: Clinical depression is usually treated in primary care with psychological therapies and antidepressant medication. However, when patients do not respond to at least two or more antidepressants within a depressive episode, they are considered to have treatment resistant depression (TRD). Previous small randomised controlled trials suggested that pramipexole, a dopamine D2/3 receptor agonist, may be effective for treating patients with unipolar and bipolar depression as it is known to influence motivational drive and reward processing. PAX-D will compare the effects of pramipexole versus placebo when added to current antidepressant medication for people with TRD. Additionally, PAX-D will investigate the mechanistic effect of pramipexole on reward sensitivity using a probabilistic decision-making task. Methods and analysis: PAX-D will assess effectiveness in the short- term (during the first 12 weeks) and in the longer-term (48 weeks) in patients with TRD from the UK. The primary outcome will be change in self-reported depressive symptoms from baseline to Week 12 post-randomisation measured using the QIDS-SR. Performance on the decision-making task will be measured at Week 0, Week 2, and Week 12. Secondary outcomes include anhedonia, anxiety, and health economic measures including quality of life, capability, wellbeing, and costs. PAX-D will also assess the adverse effects of pramipexole including impulse control difficulties. Discussion: Pramipexole is a promising augmentation agent for treatment resistant depression and may be a useful addition to existing treatment regimes. PAX-D will assess its effectiveness and test for a potential mechanism of action in patients with treatment resistant depression